452 related articles for article (PubMed ID: 33348240)
1. The utility of CYP3A activity endogenous markers for evaluating drug-drug interaction between sildenafil and CYP3A inhibitors in healthy subjects.
Lee S; Kim AH; Yoon S; Lee J; Lee Y; Ji SC; Yoon SH; Lee S; Yu KS; Jang IJ; Cho JY
Drug Metab Pharmacokinet; 2021 Feb; 36():100368. PubMed ID: 33348240
[TBL] [Abstract][Full Text] [Related]
2. Quantitative prediction of hepatic CYP3A activity using endogenous markers in healthy subjects after administration of CYP3A inhibitors or inducers.
Lee J; Yoon SH; Yi S; Kim AH; Kim B; Lee S; Yu KS; Jang IJ; Cho JY
Drug Metab Pharmacokinet; 2019 Aug; 34(4):247-252. PubMed ID: 31088714
[TBL] [Abstract][Full Text] [Related]
3. Urinary metabolic markers reflect on hepatic, not intestinal, CYP3A activity in healthy subjects.
Lee S; Lee Y; Kim AH; Yoon S; Lee J; Ji SC; Yoon SH; Lee S; Yu KS; Jang IJ; Cho JY
Drug Metab Pharmacokinet; 2021 Feb; 36():100374. PubMed ID: 33348239
[TBL] [Abstract][Full Text] [Related]
4. Effects of Strong Inhibition of Cytochrome P450 3A and UDP glucuronosyltransferase 1A9 and Strong Induction of Cytochrome P450 3A on the Pharmacokinetics, Safety, and Tolerability of Soticlestat: Two Drug-Drug Interaction Studies in Healthy Volunteers.
Yin W; Dong C; Stevenson A; Lloyd V; Petrillo M; Baratta M; Hui T; Han S
Drug Metab Dispos; 2024 Feb; 52(3):180-187. PubMed ID: 38123352
[TBL] [Abstract][Full Text] [Related]
5. Drug Interactions for Low-Dose Inhaled Nemiralisib: A Case Study Integrating Modeling, In Vitro, and Clinical Investigations.
Patel A; Wilson R; Harrell AW; Taskar KS; Taylor M; Tracey H; Riddell K; Georgiou A; Cahn AP; Marotti M; Hessel EM
Drug Metab Dispos; 2020 Apr; 48(4):307-316. PubMed ID: 32009006
[TBL] [Abstract][Full Text] [Related]
6. Drug-Drug Interaction Study to Assess the Effect of Cytochrome P450 Inhibition and Induction on the Pharmacokinetics of the Novel Cereblon Modulator Avadomide (CC-122) in Healthy Adult Subjects.
Ogasawara K; MacGorman K; Liu L; Chen J; Carayannopoulos LN; Zhou S; Palmisano M; Li Y
J Clin Pharmacol; 2019 Dec; 59(12):1620-1631. PubMed ID: 31172535
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of iberdomide and cytochrome p450 drug-drug interaction potential in vitro and in a phase 1 study in healthy subjects.
Gaudy A; Atsriku C; Ye Y; MacGorman K; Liu L; Xue Y; Surapaneni S; Palmisano M
Eur J Clin Pharmacol; 2021 Feb; 77(2):223-231. PubMed ID: 32965548
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics and Drug-Drug Interaction of Ocedurenone (KBP-5074) in vitro and in vivo.
Wang P; Liu J; Tan X; Yang F; McCabe J; Zhang J
Eur J Drug Metab Pharmacokinet; 2023 Jul; 48(4):397-410. PubMed ID: 37357226
[TBL] [Abstract][Full Text] [Related]
9. Physiologically-Based Pharmacokinetic Modeling Characterizes the CYP3A-Mediated Drug-Drug Interaction Between Fluconazole and Sildenafil in Infants.
Salerno SN; Edginton A; Gerhart JG; Laughon MM; Ambalavanan N; Sokol GM; Hornik CD; Stewart D; Mills M; Martz K; Gonzalez D;
Clin Pharmacol Ther; 2021 Jan; 109(1):253-262. PubMed ID: 32691891
[TBL] [Abstract][Full Text] [Related]
10. Ritonavir is the best alternative to ketoconazole as an index inhibitor of cytochrome P450-3A in drug-drug interaction studies.
Greenblatt DJ; Harmatz JS
Br J Clin Pharmacol; 2015 Sep; 80(3):342-50. PubMed ID: 25923589
[TBL] [Abstract][Full Text] [Related]
11. Impact of the Selective Orexin-1 Receptor Antagonist ACT-539313 on the Pharmacokinetics of the CYP3A Probe Drug Midazolam in Healthy Male Subjects.
Berger B; Kaufmann P; Koch A; Dingemanse J
J Clin Pharmacol; 2020 Jul; 60(7):931-941. PubMed ID: 32035014
[TBL] [Abstract][Full Text] [Related]
12. Physiologically based pharmacokinetic modelling to predict the clinical effect of CYP3A inhibitors/inducers on esaxerenone pharmacokinetics in healthy subjects and subjects with hepatic impairment.
Watanabe A; Ishizuka T; Yamada M; Igawa Y; Shimizu T; Ishizuka H
Eur J Clin Pharmacol; 2022 Jan; 78(1):65-73. PubMed ID: 34415382
[TBL] [Abstract][Full Text] [Related]
13. A Physiologically-Based Pharmacokinetic Modeling Approach To Predict Drug-Drug Interactions of Sonidegib (LDE225) with Perpetrators of CYP3A in Cancer Patients.
Einolf HJ; Zhou J; Won C; Wang L; Rebello S
Drug Metab Dispos; 2017 Apr; 45(4):361-374. PubMed ID: 28122787
[TBL] [Abstract][Full Text] [Related]
14. Physiologically based pharmacokinetic modeling and simulation to predict drug-drug interactions of ivosidenib with CYP3A perpetrators in patients with acute myeloid leukemia.
Prakash C; Fan B; Ke A; Le K; Yang H
Cancer Chemother Pharmacol; 2020 Nov; 86(5):619-632. PubMed ID: 32978634
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of Cytochrome P450 3A4-Mediated Drug-Drug Interaction Potential for Cobimetinib Using Physiologically Based Pharmacokinetic Modeling and Simulation.
Budha NR; Ji T; Musib L; Eppler S; Dresser M; Chen Y; Jin JY
Clin Pharmacokinet; 2016 Nov; 55(11):1435-1445. PubMed ID: 27225997
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of Ketoconazole and Its Alternative Clinical CYP3A4/5 Inhibitors as Inhibitors of Drug Transporters: The In Vitro Effects of Ketoconazole, Ritonavir, Clarithromycin, and Itraconazole on 13 Clinically-Relevant Drug Transporters.
Vermeer LM; Isringhausen CD; Ogilvie BW; Buckley DB
Drug Metab Dispos; 2016 Mar; 44(3):453-9. PubMed ID: 26668209
[TBL] [Abstract][Full Text] [Related]
17. Dose-dependent inhibition of CYP3A activity by clarithromycin during Helicobacter pylori eradication therapy assessed by changes in plasma lansoprazole levels and partial cortisol clearance to 6beta-hydroxycortisol.
Ushiama H; Echizen H; Nachi S; Ohnishi A
Clin Pharmacol Ther; 2002 Jul; 72(1):33-43. PubMed ID: 12152002
[TBL] [Abstract][Full Text] [Related]
18. Effect of rifampin and itraconazole on the pharmacokinetics of zanubrutinib (a Bruton's tyrosine kinase inhibitor) in Asian and non-Asian healthy subjects.
Mu S; Tang Z; Novotny W; Tawashi M; Li TK; Ou Y; Sahasranaman S
Cancer Chemother Pharmacol; 2020 Feb; 85(2):391-399. PubMed ID: 31875923
[TBL] [Abstract][Full Text] [Related]
19. Semi-mechanistic population pharmacokinetic drug-drug interaction modelling of a long half-life substrate and itraconazole.
Lehr T; Staab A; Trommeshauser D; Schaefer HG; Kloft C
Clin Pharmacokinet; 2010; 49(1):53-66. PubMed ID: 20000889
[TBL] [Abstract][Full Text] [Related]
20. A Novel Study Design Using Continuous Intravenous and Intraduodenal Infusions of Midazolam and Voriconazole for Mechanistic Quantitative Assessment of Hepatic and Intestinal CYP3A Inhibition.
Li X; Junge L; Taubert M; von Georg A; Dahlinger D; Starke C; Frechen S; Stelzer C; Kinzig M; Sörgel F; Jaehde U; Töx U; Goeser T; Fuhr U
J Clin Pharmacol; 2020 Sep; 60(9):1237-1253. PubMed ID: 32427354
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
